TNF Pharmaceuticals, Inc. (TNFA)
NASDAQ: TNFA · Real-Time Price · USD
3.590
-0.180 (-4.77%)
At close: Sep 9, 2025, 4:00 PM
3.750
+0.160 (4.46%)
After-hours: Sep 9, 2025, 7:50 PM EDT
TNF Pharmaceuticals Employees
TNF Pharmaceuticals had 2 employees as of December 31, 2024. The number of employees decreased by 4 or -66.67% compared to the previous year.
Employees
2
Change (1Y)
-4
Growth (1Y)
-66.67%
Revenue / Employee
n/a
Profits / Employee
-$5,263,563
Market Cap
6.34M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2 | -4 | -66.67% |
| Dec 31, 2023 | 6 | -3 | -33.33% |
| Dec 31, 2022 | 9 | 0 | - |
| Dec 31, 2021 | 9 | 3 | 50.00% |
| Dec 31, 2020 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TNFA News
- 1 day ago - TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Business Wire
- 5 days ago - TNF Pharmaceuticals Announces Closing of $7 Million Private Placement - Business Wire
- 7 days ago - PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications - Business Wire
- 7 days ago - TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications - Business Wire
- 12 days ago - TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance - Business Wire
- 21 days ago - TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation - Business Wire
- 2 months ago - TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease - Business Wire
- 4 months ago - TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists - Business Wire